This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

CareFusion Strengthens U.K. Presence With Acquisition Of Medical Products Distributor

SAN DIEGO, June 7, 2012 /PRNewswire/ --  CareFusion today announced the acquisition of U.K. Medical Limited, a leading distributor of medical products to the National Health Service (NHS) and private health care sector in the United Kingdom. Terms of the deal were not disclosed.

The acquisition, the company's fifth, is part of CareFusion's strategy to expand globally by investing to build scale, infrastructure and local capabilities in key markets. U.K. Medical has strong customer relationships and clinical marketing expertise with specialized medical technologies including products used in interventional radiology and for surgical and vascular access in acute-care hospitals.

"The acquisition further strengthens CareFusion's presence in the United Kingdom, where we have built leadership positions in infusion therapy and infection prevention," said Gordon LaFortune, executive vice president of International Commercial Operations for CareFusion. "We believe this acquisition will help us expand our long-standing partnership with U.K. Medical and better leverage the company's clinical expertise to continue to grow our Procedural Solutions business in the United Kingdom and beyond."

U.K. Medical primarily serves the National Health Service and focuses on distribution of clinically differentiated interventional and implantable single-use medical products for biopsy, cardiac, drainage, obstetrics and gynecology, non-vascular stenting, surgery and vertebroplasty. The company served as the sole U.K. distributor of CareFusion's Interventional Technologies portfolio, including soft-tissue and bone marrow biopsy needles, the AVAmax® Advanced Vertebral Augmentation System and the PleurX® Peritoneal Catheter Drainage System, which the National Institute for Health and Clinical Excellence (NICE) recently supported through published guidance for vacuum-assisted drainage of treatment-resistant, recurrent malignant ascites. Over the past three years, U.K. Medical has contributed to a nearly 50 percent growth of CareFusion's Interventional Technologies portfolio in the United Kingdom. The company also markets medical products for approximately 10 additional suppliers.

"For more than 30 years, we have served the NHS and private medical sector with high-quality, high-technology medical products to help improve patient care pathways," said Jim Mackenzie, chairman of U.K. Medical. "We look forward to continuing our track record of growth and innovation with CareFusion."

U.K. Medical has nearly 40 employees and is headquartered in Sheffield, United Kingdom. CareFusion currently employs approximately 350 people in the United Kingdom.

About CareFusionCareFusion (NYSE: CFN) is a global corporation serving the health care industry with products and services that help hospitals measurably improve the safety and quality of care. The company develops market-leading technologies including Alaris® infusion pumps, Pyxis® automated dispensing and patient identification systems, AVEA®, Air Life™ and LTV® series ventilation and respiratory products, ChloraPrep® skin prep products, MedMined® services for data mining surveillance, Nicolet™ neurological monitoring and diagnostic products, V. Mueller® surgical instruments, and an extensive line of products that support interventional medicine. CareFusion employs more than 14,000 people across its global operations. More information may be found at www.carefusion.com.

(Logo: http://photos.prnewswire.com/prnh/20100706/CAREFUSIONLOGO)





1 of 2

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 17,098.45 +18.88 0.11%
S&P 500 2,003.37 +6.63 0.33%
NASDAQ 4,580.2710 +22.5760 0.50%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs